Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
Delayed Quote. Delayed London Stock Exchange - 09/27 11:35:26 am
1387.2 GBX   -0.06%
09/25Bluebell Capital Provides Information to the Shareholders
CI
09/24GLAXOSMITHKLINE ( '') (FORM 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)
PU
09/24European ADRs Move Lower in Friday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline : Gsk - Files For Licensure Of Mmr Vaccine In U.S.

08/02/2021 | 12:18pm EDT

Aug 2 (Reuters) - GlaxoSmithKline PLC:

* GSK - FILES FOR LICENSURE OF MMR VACCINE IN U.S.

* GSK - SUBMITTED A BLA TO U.S. FDA FOR PRIORIX, SEEKING APPROVAL FOR USE IN ACTIVE IMMUNIZATION AGAINST INFECTION BY MEASLES, MUMPS AND RUBELLA (MMR) Source text for Eikon: Further company coverage:


ę Reuters 2021
All news about GLAXOSMITHKLINE PLC
09/25Bluebell Capital Provides Information to the Shareholders
CI
09/24GLAXOSMITHKLINE ( '') (FORM 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)
PU
09/24European ADRs Move Lower in Friday Trading
MT
09/24GLAXOSMITHKLINE : UBS sticks Neutral
MD
09/24GLAXOSMITHKLINE : Federal Circuit Vacates Judgment, Reinstates Jury's Verdict Of Induced I..
AQ
09/23GLOBAL MARKETS LIVE : Valneva,Boeing, Facebook, Kubota, Otis...
09/23Activist Bluebell Capital Takes Small Stake in GSK to Push for Board Change -FT
DJ
09/23GLAXOSMITHKLINE : Survey Shows More People In Favor Of Vaccinations After COVID-19
MT
09/22GLAXOSMITHKLINE : CEO Faces Additional Pressure as Bluebell Joins Elliott in Demanding Man..
MT
09/22GLAXOSMITHKLINE : Activist investor Bluebell takes stake in GSK to challenge chief exec
AQ
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Financials
Sales 2021 33 307 M 45 635 M 45 635 M
Net income 2021 3 857 M 5 284 M 5 284 M
Net Debt 2021 20 885 M 28 616 M 28 616 M
P/E ratio 2021 18,2x
Yield 2021 5,77%
Capitalization 69 428 M 95 179 M 95 127 M
EV / Sales 2021 2,71x
EV / Sales 2022 2,53x
Nbr of Employees 94 066
Free-Float 92,2%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 13,87 GBX
Average target price 1 604,94 GBX
Spread / Average Target 11 470%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC3.43%94 962
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037